Investor Presentation Q1 2023
20
Investor presentation
First three months of 2023
Novo Nordisk has leading positions in diabetes, obesity and
haemophilia
Novo NordiskⓇ
Diabetes care
DKK
billion
1000
Obesity care
DKK
billion
#1
50%
40
40
Haemophilia
DKK
billion
#1
100%
100
#3
50%
800
40%
80%
80
40%
30
600
30%
60%
60
30%
20
20
400
20%
40%
40
40
20%
10
200
CAGR¹ value: 15.3%
10%
CAGR² value: 80.7%
20%
20
20
10%
CAGR³ value: 5.9%
0%
0
Feb
2023
Feb
2021
0
Feb
2018
Market value
NN value market share (RHS)
Global market position
Market value
0%
0
Feb
2023
FY
2019
Market value
NN value market share (RHS)
Global market position
0%
FY
2022
-NN value market share (RHS)
Global market position
1 CAGR for 5-year period; 2 CAGR for 2-year period; 3 CAGR for 3-year period; RHS: Right-hand side; Note: Annual sales figures for haemophilia A, B and bypassing agent segments, plasma derived products excluded except FeibaⓇ;
Source: Company reports for haemophilia market; IQVIA MAT, Feb 2023; Note: Diabetes and Obesity care market values are based on list prices in the US.
NN: Novo Nordisk.View entire presentation